Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference

BALA CYNWYD, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a panel discussion and 1x1 investor meetings at the Citi 18th Annual BioPharma Conference, taking place in Boston, MA from September 5 - 7, 2023.

Details on the panel discussion can be found below.

Title: Rare Neurological DiseasesDate: Wednesday, September 6, 2023Time: 8:50 – 9:35 AM ET

About Larimar TherapeuticsLarimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:Joyce AllaireLifeSci Advisors[email protected](212) 915-2569

Company Contact:Michael CelanoChief Financial Officer[email protected](484) 414-2715

You May Also Be Interested In

• AMREP Reports First Quarter Fiscal 2027 Results
• Interim results for the six months ended June 30, 2026
• Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)